Long Grove receives FDA nod for premix Vasopressin
Long Grove Pharmaceuticals continues to meet the critical care needs of hospital pharmacies with the Food and Drug Administration’s approval of premix Vasopressin in its most commonly used concentrations.
The company will offer the following concentrations in early Fall 2024:
- 20 units/100 mL (0.2 units/mL) in 0.9% sodium chloride
- 40 units/100 mL (0.4 units/mL) in 0.9% sodium chloride
[Read more: Long Grove launches premix norepinephrine]
“We’re focusing on the areas of greatest need in critical care, and the FDA approval of Premix Vasopressin demonstrates this commitment. Our extensive hospital pharmacy and pharmaceutical industry experience enables us to develop differentiated pharmaceuticals designed to specifically meet our customers’ and patients’ greatest areas of need,” said Peter Karas, chief commercial officer at Long Grove Pharmaceuticals.
Vasopressin in sodium chloride injection is generally used to increase blood pressure when other measures have failed for patients in critical hypotensive shock. Hospital pharmacies throughout the U.S. have a critical need for premix vasopressin with a long shelf life. Long Grove’s new offering will provide immediate value to hospital pharmacies and their patients.
Long Grove Pharmaceuticals introduced its first product to customers in 2022. The company is improving the generic supply chain by developing complex formulations, addressing manufacturing challenges and achieving regulatory approvals in difficult environments.
[Read more: Long Grove launches premix norepinephrine]
“We believe that collaborative and reliable partnerships with manufacturers, developers, suppliers, and customers are essential for sustaining a healthy drug supply chain,” Karas said.